PT4218408T - Roedores que expressam desoxinucleotidil-transferase terminal exógena - Google Patents

Roedores que expressam desoxinucleotidil-transferase terminal exógena

Info

Publication number
PT4218408T
PT4218408T PT231510942T PT23151094T PT4218408T PT 4218408 T PT4218408 T PT 4218408T PT 231510942 T PT231510942 T PT 231510942T PT 23151094 T PT23151094 T PT 23151094T PT 4218408 T PT4218408 T PT 4218408T
Authority
PT
Portugal
Prior art keywords
expressing exogenous
terminal deoxynucleotidyltransferase
exogenous terminal
rodents expressing
rodents
Prior art date
Application number
PT231510942T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of PT4218408T publication Critical patent/PT4218408T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/1264—DNA nucleotidylexotransferase (2.7.7.31), i.e. terminal nucleotidyl transferase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07031—DNA nucleotidylexotransferase (2.7.7.31), i.e. terminal deoxynucleotidyl transferase
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Environmental Sciences (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
PT231510942T 2016-06-03 2017-06-02 Roedores que expressam desoxinucleotidil-transferase terminal exógena PT4218408T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662345524P 2016-06-03 2016-06-03

Publications (1)

Publication Number Publication Date
PT4218408T true PT4218408T (pt) 2025-03-26

Family

ID=59215996

Family Applications (2)

Application Number Title Priority Date Filing Date
PT177332236T PT3462853T (pt) 2016-06-03 2017-06-02 Animais não humanos que expressam desoxinucleotidiltransferase terminal exógena
PT231510942T PT4218408T (pt) 2016-06-03 2017-06-02 Roedores que expressam desoxinucleotidil-transferase terminal exógena

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PT177332236T PT3462853T (pt) 2016-06-03 2017-06-02 Animais não humanos que expressam desoxinucleotidiltransferase terminal exógena

Country Status (25)

Country Link
US (2) US10980221B2 (enExample)
EP (3) EP4567104A3 (enExample)
JP (4) JP7053499B2 (enExample)
KR (3) KR102483193B1 (enExample)
CN (3) CN109640644B (enExample)
AU (2) AU2017272337C1 (enExample)
BR (1) BR112018074794A2 (enExample)
CA (1) CA3026088A1 (enExample)
CY (1) CY1126063T1 (enExample)
DK (2) DK4218408T3 (enExample)
ES (2) ES2941810T3 (enExample)
FI (2) FI4218408T3 (enExample)
HR (2) HRP20250471T1 (enExample)
HU (2) HUE071052T2 (enExample)
IL (2) IL263160B2 (enExample)
LT (2) LT4218408T (enExample)
MX (3) MX385681B (enExample)
PL (2) PL3462853T3 (enExample)
PT (2) PT3462853T (enExample)
RS (2) RS66700B1 (enExample)
RU (1) RU2753585C2 (enExample)
SG (2) SG11201810757YA (enExample)
SI (2) SI4218408T1 (enExample)
SM (2) SMT202300132T1 (enExample)
WO (1) WO2017210586A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20181866T1 (hr) 2013-02-22 2019-01-25 Regeneron Pharmaceuticals, Inc. Miševi koji izražavaju humanizirane komplekse glavne histokompatibilnosti
RS66700B1 (sr) 2016-06-03 2025-05-30 Regeneron Pharma Glodari koji eksprimiraju egzogenu terminalnu dezoksinukleotidil transferazu
WO2019113065A1 (en) 2017-12-05 2019-06-13 Regeneron Pharmaceuticals, Inc. Non-human animals having an engineered immunoglobulin lambda light chain and uses thereof
EP3772927B1 (en) 2018-03-24 2025-01-15 Regeneron Pharmaceuticals, Inc. Genetically modified mice or rats for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof
US20210238312A1 (en) * 2018-06-13 2021-08-05 The Children's Medical Center Corporation Methods and compositions relating to high-throughput models for antibody discovery and/or optimization
IL318469A (en) 2018-06-14 2025-03-01 Regeneron Pharma Non-human animals capable of reorganizing transgenic DH-DH, and their uses
SG11202107589PA (en) * 2019-02-22 2021-08-30 Regeneron Pharma Rodents having genetically modified sodium channels and methods of use thereof
US20220330532A1 (en) 2019-06-05 2022-10-20 Regeneron Pharmaceuticals, Inc. Non-human animals having a limited lambda light chain repertoire expressed from the kappa locus and uses thereof
KR20220114026A (ko) * 2019-12-12 2022-08-17 디엔에이 스크립트 폴리뉴클레오타이드의 주형-부재 효소 합성을 위한 키메라 말단 데옥시뉴클레오타이드 전달효소
CN111057754B (zh) * 2019-12-27 2021-01-12 四川省医学科学院.四川省人民医院实验动物研究所 鉴定适用于hbv研究的动物模型的方法和应用
CN115175559A (zh) 2020-01-28 2022-10-11 瑞泽恩制药公司 包含人源化pnpla3基因座的非人动物及其使用方法
CN116075221A (zh) * 2020-04-21 2023-05-05 瑞泽恩制药公司 具有人源化cxcl13基因的非人动物
TW202229328A (zh) 2020-09-11 2022-08-01 美商再生元醫藥公司 抗原特異性抗體之鑑定及產生
JP2024500399A (ja) 2020-12-16 2024-01-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒト化Ｆｃアルファ受容体を発現するマウス
US12371475B2 (en) 2020-12-23 2025-07-29 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding anchor modified antibodies and uses thereof
JP2024512702A (ja) 2021-03-31 2024-03-19 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｔｃｒβレパートリーの改善された多様性を伴うヒト化細胞免疫系の構成要素を含む、遺伝的に改変されたマウス
KR20250077529A (ko) * 2022-09-22 2025-05-30 리제너론 파아마슈티컬스, 인크. 인간 세포 면역계의 성분을 발현하는, 유전자적으로 변형된 마우스
NL2037811B1 (en) 2024-05-29 2025-12-12 Univ Oslo Treatment for Cancer

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US7041871B1 (en) 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
GB9119338D0 (en) 1991-09-10 1991-10-23 Inst Of Animal Physiology And Control of gene expression
US5523226A (en) * 1993-05-14 1996-06-04 Biotechnology Research And Development Corp. Transgenic swine compositions and methods
US5512295A (en) 1994-11-10 1996-04-30 The Board Of Trustees Of The Leland Stanford Junior University Synthetic liposomes for enhanced uptake and delivery
US6001349A (en) 1995-02-22 1999-12-14 Therion Biologics Corporation Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6770291B2 (en) 1996-08-30 2004-08-03 The United States Of America As Represented By The Department Of Health And Human Services Liposome complexes for increased systemic delivery
US7001614B2 (en) 1996-08-19 2006-02-21 The United States Of America As Represented By The Department Of Health And Human Services Liposome complexes for increased systemic delivery
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
US7112338B2 (en) 1997-03-12 2006-09-26 The Regents Of The University Of California Cationic liposome delivery of taxanes to angiogenic blood vessels
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6749863B1 (en) 1997-11-19 2004-06-15 Georgetown University Targeted liposome gene delivery
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
GB9823930D0 (en) 1998-11-03 1998-12-30 Babraham Inst Murine expression of human ig\ locus
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CA2440676A1 (en) 2001-03-22 2002-10-03 Abbott Gmbh & Co. Kg Transgenic animals expressing antibodies specific for genes of interest and uses thereof
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US8093357B2 (en) 2002-03-01 2012-01-10 Xencor, Inc. Optimized Fc variants and methods for their generation
US20090042291A1 (en) 2002-03-01 2009-02-12 Xencor, Inc. Optimized Fc variants
AU2003297155B2 (en) 2002-12-16 2010-03-18 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant vaccine viruses expressing IL-15 and methods of using the same
US20060153826A1 (en) 2003-01-28 2006-07-13 Sylvain Arnould Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
US8218805B2 (en) 2003-10-11 2012-07-10 Charles Hornback Wireless speaker system for use with ceiling fans
WO2005063815A2 (en) 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
EP1773383B1 (en) 2004-05-27 2012-09-12 Jon A. Weidanz Antibodies as t cell receptor mimics, methods of production and uses thereof
EP1802193B1 (en) 2004-10-19 2014-04-30 Regeneron Pharmaceuticals, Inc. Method for generating a mouse homozygous for a genetic modification
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
US20060222653A1 (en) 2004-11-12 2006-10-05 Xencor, Inc. Antibodies operably linked to selected chemoattractants
US20060275282A1 (en) 2005-01-12 2006-12-07 Xencor, Inc. Antibodies and Fc fusion proteins with altered immunogenicity
CN101263158B (zh) * 2005-08-03 2011-12-28 人类多克隆治疗股份有限公司 表达人源化免疫球蛋白的转基因动物中b细胞凋亡的抑制
JP2009504787A (ja) 2005-08-19 2009-02-05 シーラス コーポレイション 抗体によって媒介される免疫応答の増強
EP4174179B1 (en) 2005-08-23 2025-05-07 The Trustees of the University of Pennsylvania Rna containing modified nucleosides and methods of use thereof
AU2007235496B2 (en) 2006-03-31 2013-11-21 E. R. Squibb & Sons, L.L.C. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
PT2336329E (pt) 2007-06-01 2012-12-24 Omt Inc Composições e métodos para inibição de genes de imunoglobulina endógena e produção de anticorpos transgénicos humanos idiotípicos
EP2207564B1 (en) 2007-10-18 2016-10-05 Bavarian Nordic A/S Use of mva to treat prostate cancer
US8225343B2 (en) 2008-01-11 2012-07-17 Sony Computer Entertainment America Llc Gesture cataloging and recognition
CN102123582B (zh) 2008-06-27 2015-09-30 莫鲁斯有限公司 产生抗体的非人哺乳动物
KR102362774B1 (ko) 2008-09-30 2022-02-15 아블렉시스, 엘엘씨 키메라 항체의 제조를 위한 인간 이외의 포유동물
US8691502B2 (en) 2008-10-31 2014-04-08 Tremrx, Inc. T-cell vaccination with viral vectors via mechanical epidermal disruption
NO2792236T3 (enExample) 2009-07-08 2018-04-14
RU2425880C2 (ru) * 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Способ получения трансгенных мышей
CN102711449B (zh) 2009-12-10 2015-01-07 瑞泽恩制药公司 生产重链抗体的小鼠
US20120021409A1 (en) * 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
US20130185821A1 (en) 2010-02-08 2013-07-18 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
PL3095871T3 (pl) 2010-02-08 2019-10-31 Regeneron Pharma Mysz zawierająca wspólny łańcuch lekki
JP2013523098A (ja) 2010-03-29 2013-06-17 ザイムワークス，インコーポレイテッド 強化又は抑制されたエフェクター機能を有する抗体
ES2641920T3 (es) 2010-03-31 2017-11-14 Ablexis, Llc Ingeniería genética de animales no humanos para la producción de anticuerpos quiméricos
ME02902B (me) 2010-06-22 2018-04-20 Regeneron Pharma Transgeni miševi sa modifikovanim lokusom endogenog lambda imunoglobulina
DK2597945T3 (da) 2010-07-26 2020-09-21 Trianni Inc Transgene dyr og fremgangsmåder til anvendelse deraf
RS55495B1 (sr) 2010-08-02 2017-04-28 Regeneron Pharma Miševi koji stvaraju vezujuće proteine koji sadrže vl domene
ES2946169T3 (es) 2011-02-25 2023-07-13 Regeneron Pharma Ratones ADAM6
JP5893258B2 (ja) 2011-03-31 2016-03-23 フェリカネットワークス株式会社 情報処理装置および方法、並びにプログラム
US20130018582A1 (en) 2011-07-13 2013-01-17 Miller Paul A Inertial Navigation Common Azimuth Reference Determination System and Method
IL273982B2 (en) 2011-08-05 2023-03-01 Regeneron Pharma Humanized mice possess a universal light chain
EP2758535B1 (en) 2011-09-19 2016-11-09 Kymab Limited Antibodies, variable domains&chains tailored for human use
CA2791109C (en) 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
KR20250021626A (ko) 2011-10-17 2025-02-13 리제너론 파마슈티칼스 인코포레이티드 제한된 면역글로불린 중쇄 마우스
ES2858978T3 (es) 2011-10-28 2021-09-30 Regeneron Pharma Ratones con receptores de linfocitos T genéticamente modificados
ES2741649T3 (es) 2011-10-28 2020-02-11 Regeneron Pharma Ratones con complejo mayor de histocompatibilidad modificado genéticamente
CA2853731C (en) 2011-10-28 2021-05-18 Regeneron Pharmaceuticals, Inc. Humanized il-6 and il-6 receptor
CN104039133B (zh) 2011-10-28 2018-05-04 瑞泽恩制药公司 表达嵌合主要组织相容性复合物(mhc)ii类分子的基因修饰小鼠
US9043996B2 (en) 2011-10-28 2015-06-02 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex animals
US9591835B2 (en) 2011-10-28 2017-03-14 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex animals
WO2013063702A1 (en) 2011-11-04 2013-05-10 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
US9120662B2 (en) 2011-11-14 2015-09-01 Susan A. Thomson Gathering and dispensing scoop with gate valve
US9547499B2 (en) 2011-12-09 2017-01-17 Microsoft Technology Licensing, Llc Device configuration with cached pre-assembled driver state
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
LT2883449T (lt) 2012-03-16 2018-05-10 Regeneron Pharmaceuticals, Inc. Histidinu modifikuoti lengvosios grandinės antikūnai ir juos gaminantys genetiškai modifikuoti graužikai
EP3539374A1 (en) 2012-03-16 2019-09-18 Regeneron Pharmaceuticals, Inc. Non-human animals expressing ph-sensitive immunoglobulin sequences
CN106318951A (zh) * 2012-03-16 2017-01-11 瑞泽恩制药公司 生产具有ph依赖性结合特性的抗原结合蛋白的小鼠
JP5920830B2 (ja) 2012-09-28 2016-05-18 シスメックス株式会社 試料調製装置および細胞分析装置
EP3653049B1 (en) 2012-12-14 2023-09-13 OmniAb, Inc. Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same
EP2840892B1 (en) 2013-02-20 2018-04-18 Regeneron Pharmaceuticals, Inc. Non-human animals with modified immunoglobulin heavy chain sequences
KR102714111B1 (ko) 2013-02-20 2024-10-11 리제너론 파아마슈티컬스, 인크. 사람화된 ｔ-세포 보조-수용체를 발현하는 마우스
HRP20181866T1 (hr) 2013-02-22 2019-01-25 Regeneron Pharmaceuticals, Inc. Miševi koji izražavaju humanizirane komplekse glavne histokompatibilnosti
KR20200136508A (ko) 2013-04-16 2020-12-07 리제너론 파마슈티칼스 인코포레이티드 랫트 게놈의 표적화된 변형
US9783618B2 (en) * 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
JP6174811B2 (ja) 2013-12-11 2017-08-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ゲノムの標的改変のための方法及び組成物
JP6636498B2 (ja) 2014-03-21 2020-01-29 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 単一ドメイン結合タンパク質を作る非ヒト動物
RU2016141123A (ru) 2014-03-21 2018-04-23 Регенерон Фармасьютикалз, Инк. Антигенсвязывающие белки vl, проявляющие различные связывающие характеристики
RU2704283C9 (ru) 2014-06-06 2020-02-07 Регенерон Фармасьютикалз, Инк. Способы и композиции для модификации целевого локуса
BR112016029650A2 (pt) * 2014-06-19 2017-10-24 Regeneron Pharma roedor, polipeptídeo pd-1, célula isolada ou tecido de roedor, célula-tronco embrionária de roedor, métodos de produzir um roedor, de reduzir o crescimento de tumor em um roedor, de matar células tumorais em um roedor e de avaliar as propriedades farmacocinéticas de uma droga que direciona pd-1 humano, e, modelo de tumor de roedor?
CA2953499C (en) 2014-06-23 2023-10-24 Regeneron Pharmaceuticals, Inc. Nuclease-mediated dna assembly
PT3161128T (pt) 2014-06-26 2018-11-21 Regeneron Pharma Métodos e composições para modificações genéticas alvejadas e métodos de utilização
US20160081314A1 (en) * 2014-09-19 2016-03-24 Regeneron Pharmaceuticals, Inc. Chimeric Antigen Receptors
CN107666828B (zh) 2015-04-06 2021-04-09 瑞泽恩制药公司 非人动物中的人源化t细胞介导的免疫应答
RS66700B1 (sr) 2016-06-03 2025-05-30 Regeneron Pharma Glodari koji eksprimiraju egzogenu terminalnu dezoksinukleotidil transferazu

Also Published As

Publication number Publication date
HUE071052T2 (hu) 2025-07-28
EP4567104A3 (en) 2025-09-24
MX385681B (es) 2025-03-18
PL4218408T3 (pl) 2025-06-09
ES3018427T3 (es) 2025-05-16
LT3462853T (lt) 2023-03-27
PT3462853T (pt) 2023-04-21
CN116458475A (zh) 2023-07-21
ES2941810T3 (es) 2023-05-25
EP3462853A1 (en) 2019-04-10
KR20230156162A (ko) 2023-11-13
CN109640644B (zh) 2021-10-26
IL263160A (en) 2018-12-31
WO2017210586A8 (en) 2018-05-03
US20170347633A1 (en) 2017-12-07
RU2753585C2 (ru) 2021-08-18
NZ749707A (en) 2024-04-26
RU2018144954A3 (enExample) 2020-10-02
CN113907043B (zh) 2023-08-01
SG11201810757YA (en) 2018-12-28
KR102598120B1 (ko) 2023-11-07
IL263160B1 (en) 2023-09-01
DK4218408T3 (da) 2025-04-14
DK3462853T3 (da) 2023-04-03
EP4567104A2 (en) 2025-06-11
LT4218408T (lt) 2025-05-12
RS64216B1 (sr) 2023-06-30
CN109640644A (zh) 2019-04-16
RS66700B1 (sr) 2025-05-30
EP3462853B1 (en) 2023-03-01
JP2025020339A (ja) 2025-02-12
SG10201914014XA (en) 2020-03-30
FI3462853T3 (fi) 2023-04-05
AU2017272337A8 (en) 2019-03-14
MX2018014982A (es) 2019-09-18
CA3026088A1 (en) 2017-12-07
AU2017272337C1 (en) 2024-02-29
FI4218408T3 (fi) 2025-04-25
JP7586960B2 (ja) 2024-11-19
EP4218408B1 (en) 2025-03-19
IL263160B2 (en) 2024-01-01
RU2018144954A (ru) 2020-07-14
PL3462853T3 (pl) 2023-06-26
JP7274018B2 (ja) 2023-05-15
KR20190031447A (ko) 2019-03-26
US20210195877A1 (en) 2021-07-01
AU2017272337B9 (en) 2023-12-14
MX2021010351A (es) 2021-10-13
US10980221B2 (en) 2021-04-20
WO2017210586A1 (en) 2017-12-07
US12295354B2 (en) 2025-05-13
SI3462853T1 (sl) 2023-05-31
JP2019521668A (ja) 2019-08-08
KR102483193B1 (ko) 2023-01-04
IL304839A (en) 2023-09-01
MX2021010352A (es) 2021-10-22
HRP20230497T1 (hr) 2023-07-21
HUE061619T2 (hu) 2023-07-28
AU2024200577A1 (en) 2024-02-22
CY1126063T1 (el) 2023-11-15
JP7053499B2 (ja) 2022-04-12
EP4218408A1 (en) 2023-08-02
HRP20250471T1 (hr) 2025-06-06
BR112018074794A2 (pt) 2019-03-12
JP2023093729A (ja) 2023-07-04
KR102784608B1 (ko) 2025-03-27
JP2022088597A (ja) 2022-06-14
SMT202500152T1 (it) 2025-05-12
KR20230006053A (ko) 2023-01-10
AU2017272337B2 (en) 2023-11-09
SI4218408T1 (sl) 2025-06-30
SMT202300132T1 (it) 2023-05-12
AU2017272337A1 (en) 2019-01-24
CN113907043A (zh) 2022-01-11

Similar Documents

Publication Publication Date Title
IL304839A (en) Non-human animals expressing exogenous terminal deoxynucleotidyltransferase
PL3053430T3 (pl) Prasa belująca
SG11201700936RA (en) Connecting terminal
PL3262921T3 (pl) Prasa
SI3176879T1 (sl) Električni priključek
IL255466A (en) Worthioxetine pyroglutamate
IL273792B (en) Bait
PL3366109T3 (pl) Prasa belująca w bele okrągłe
SI3058805T1 (sl) Balirka za seno
PL3369307T3 (pl) Prasa belująca
SI3058804T1 (sl) Balirka za seno
GB201521121D0 (en) An animal feeder
PL3369306T3 (pl) Prasa kostkująca
ZAA201701890S (en) Beehives
PH32015000448S1 (en) Rat bait
TWM490130U (en) Micro-connector terminal structure improvement
TWM489499U (en) Electric mosquito swatter
TWM490218U (en) Electric mosquito swatter
GB201510837D0 (en) Zoo etc animals
GB201518289D0 (en) Monster scanner
GB201520180D0 (en) An extermination system
PL3250085T3 (pl) System terminala
GB201508874D0 (en) Two terminal amplifier
GB201402816D0 (en) Crop Pest Reducer
HUP1400570A2 (en) Vibrating electrical artificial bait